Group 1 - The board meeting of Shanghai Pharmaceuticals was held on August 28, 2025, with all nine directors present, meeting the legal requirements for quorum [1] - The board approved a proposal that had previously been reviewed and approved by the audit committee and independent directors, with a unanimous vote of 9 in favor and 0 against [1][2] - The chairman of the board, Yang Qiuhua, presided over the meeting, which included attendance from supervisors and some senior management [1] Group 2 - Yang Qiuhua, a related director, abstained from voting on the proposal, while the other eight non-related directors voted in favor, resulting in a vote of 8 in favor and 0 against [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [6][17]. Core Insights - The company reported a revenue of 141.59 billion yuan (+1.6%) and a net profit attributable to shareholders of 4.459 billion yuan (+51.6%) for the first half of 2025. The significant net profit growth was primarily due to a one-time special gain of approximately 1.68 billion yuan from a change in accounting treatment for a joint venture [3][4]. - The commercial segment showed steady growth, with a revenue of 129.4 billion yuan (+2.2%) and a net profit of 1.79 billion yuan (+0.1%) in H1 2025. Notably, the innovative drug business achieved a revenue of 24.2 billion yuan (+22.6%) [4]. - The industrial segment's performance improved in Q2 2025, with a revenue of 12.16 billion yuan (-4.5%) and a net profit of 1.15 billion yuan (-12.3%) for H1 2025. The company is advancing multiple innovative drug pipelines, including NDA applications and clinical trials [5]. Financial Summary - The company adjusted its profit forecasts for 2025-2027, expecting net profits of 6.22 billion yuan, 4.99 billion yuan, and 5.5 billion yuan respectively, with corresponding P/E ratios of 11, 14, and 13 times [6][12]. - The financial data indicates a gross margin of 10.84% (-0.91 percentage points) and a net margin of 4.41% (+2.39 percentage points) for Q2 2025 [5][12]. - The company’s total revenue is projected to grow from 275.25 billion yuan in 2024 to 309.97 billion yuan in 2027, with a net profit forecasted to increase from 4.55 billion yuan in 2024 to 5.51 billion yuan in 2027 [7][12].

Core Insights - Shanghai Pharmaceuticals (601607.SH) reported a total operating revenue of 141.593 billion, ranking first among disclosed peers, with a year-on-year increase of 1.56% [1] - The net profit attributable to shareholders reached 4.459 billion, also ranking first among peers, reflecting a significant year-on-year increase of 51.56% [1] - The net cash flow from operating activities was 989 million, ranking fourth among peers, with a substantial year-on-year increase of 91.98% [1] Financial Metrics - The latest debt-to-asset ratio stands at 62.68%, a decrease of 0.17 percentage points from the same period last year [3] - The gross profit margin is reported at 10.55%, an increase of 0.29 percentage points from the previous quarter [3] - Return on equity (ROE) is at 5.94%, ranking fourth among peers, with a year-on-year increase of 1.73 percentage points [3] - The diluted earnings per share (EPS) is 1.20 yuan, ranking second among peers, with a year-on-year increase of 51.90% [3] - The total asset turnover ratio is 0.62 times, ranking seventh among peers [3] - The inventory turnover ratio is 3.17 times, ranking eleventh among peers [3] Shareholder Structure - The number of shareholders is 85,100, with the top five shareholders holding a total of 2.091 billion shares, accounting for 56.40% of the total share capital [3] - The top five shareholders are: 1. Shanghai Pharmaceuticals (Group) Co., Ltd. - 19.3% 2. Yunnan Baiyao Group Co., Ltd. - 17.9% 3. Shanghai Shun International Investment Co., Ltd. - 8.10% 4. Shanghai Shun (Group) Co., Ltd. - 5.98% 5. Shanghai Tandong Enterprise Consulting Service Co., Ltd. - 5.04% [3]

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of the "2025 Semi-Annual Report and Summary" by the company's eighth board of directors during its 24th meeting [2] Group 1 - The announcement was made on the evening of August 28 [2] - The report includes financial performance and strategic insights for the first half of 2025 [2]

Core Viewpoint - Shanghai Pharmaceuticals (601607)(02607) reported a mid-year performance for 2025, showing a slight increase in revenue but a significant rise in net profit due to a change in accounting treatment for a subsidiary [1] Financial Performance - The company's operating revenue was approximately 141.59 billion yuan, representing a year-on-year growth of 1.56% [1] - The net profit attributable to shareholders was about 4.46 billion yuan, reflecting a year-on-year increase of 51.56% [1] - Basic earnings per share stood at 1.2 yuan [1] Special Accounting Adjustments - The increase in net profit was primarily due to a one-time special gain resulting from the change in accounting treatment for Hutchison Whampoa from equity method accounting to subsidiary accounting [1] - Excluding this one-time special gain, the net profit attributable to shareholders was 2.78 billion yuan, which represents a year-on-year decline of 2.06% [1]

Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 141.59 billion yuan for the first half of 2025, with a year-on-year growth of 1.56%, and a net profit of 4.46 billion yuan, reflecting a significant increase of 51.56% [1] Group 1: Financial Performance - The pharmaceutical manufacturing segment generated sales of 12.16 billion yuan, while the pharmaceutical commercial segment achieved sales of 129.43 billion yuan, with the latter growing by 2.17% year-on-year [1] - The company’s net profit attributable to shareholders reached 4.46 billion yuan, with contributions from the industrial segment at 1.15 billion yuan and the commercial segment at 1.79 billion yuan [1] Group 2: R&D and Innovation - R&D investment totaled 1.15 billion yuan, accounting for 9.44% of the pharmaceutical manufacturing sales, with 959 million yuan specifically allocated for R&D expenses [2] - The company has a pipeline of 56 new drugs, including 44 innovative drugs, with significant progress in clinical trials for several candidates [2] - The company is advancing its research platforms, achieving milestones in drug discovery and clinical trials, including the completion of Phase II trials for multiple candidates [2] Group 3: Strategic Initiatives - The company is enhancing its open-source innovation ecosystem by collaborating with high-growth enterprises and establishing a drug technology validation center with Shanghai Jiao Tong University [3] - The company is focusing on marketing transformation and lean management to improve industrial operations, achieving cost savings of approximately 6.98 million yuan through centralized procurement [4] Group 4: Business Expansion - The company completed the acquisition of a 10% stake in Hehuang Pharmaceutical, which has shown growth in key performance indicators [5] - The company is implementing a "big health OTC + new retail" strategy, including the formation of a professional live-streaming team to explore new business models [6] Group 5: Commercial Performance - The pharmaceutical commercial segment is leveraging technological innovation and digitalization to maintain growth, with significant increases in contract sales and strategic partnerships [7][8] - The import agency business added 25 new product specifications, generating sales of 17.5 billion yuan, a year-on-year increase of 11.7% [8] - The company launched an integrated new retail strategy, enhancing patient-centered services through its retail network and supply chain [8]

Core Viewpoint - Shanghai Pharmaceuticals (02607) reported a mid-year performance for 2025, showing a slight increase in revenue but a significant rise in net profit due to accounting changes [1] Financial Performance - The company's operating revenue was approximately 141.59 billion, reflecting a year-on-year growth of 1.56% [1] - The net profit attributable to shareholders was about 4.46 billion, marking a substantial year-on-year increase of 51.56% [1] - Basic earnings per share stood at 1.2 yuan [1] Special Accounting Changes - The increase in net profit was primarily attributed to a one-time special gain resulting from the change in accounting treatment of Hutchison Whampoa from equity method accounting to subsidiary accounting [1] - Excluding this one-time special gain, the net profit attributable to shareholders was 2.78 billion, which represents a year-on-year decline of 2.06% [1]

Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 141.593 billion RMB for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 12.160 billion RMB, a decrease of 4.50% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 129.433 billion RMB, an increase of 2.17% year-on-year [1] Profit Analysis - The net profit attributable to shareholders was 4.459 billion RMB, representing a year-on-year increase of 51.56%, primarily due to a one-time special gain from changing the accounting treatment of a joint venture to a subsidiary [1] - Excluding one-time special gains and losses, the net profit attributable to shareholders was 2.782 billion RMB, showing a year-on-year decline of 2.06% [1] Strategic Focus - The company emphasizes steady progress and innovation, focusing on strengthening core competencies and enhancing development momentum through a "three horizontal and three vertical" development system [1] - Shanghai Pharmaceuticals has been recognized in the Fortune Global 500 and ranked 407th, while also being listed among the top 25 most valuable pharmaceutical brands globally, ranking 19th [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607) 截至2025年6月30日六個月未經審計中期業績公告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）欣然發佈本公司及其附屬公司 （合稱「本集團」）截至2025年6月30日六個月的中期業績。該中期業績乃根據中國企業會 計準則編製，未經審計。董事會及審計委員會已審閱並確認此中期業績。 本公司截至2025年6月30日六個月的中期報告全文附於本公告後。正式中期報告 將於適當時候在香港聯合交易所有限公司的網站(www.hkexnews.hk)和本公司網站 (www.sphchina.com)刊登。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年八月二十九日 於本公告日期，本公司的執行董事為楊秋華 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) reported a revenue of 141.593 billion yuan for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] - The company's net profit attributable to shareholders reached 4.459 billion yuan, marking a significant year-on-year increase of 51.56% [1] - However, the company's net profit excluding non-recurring items was 2.1 billion yuan, which represents a year-on-year decline of 22.38% [1] - Basic earnings per share stood at 1.20 yuan [1] Financial Performance - Revenue for the period was 141.593 billion yuan, up 1.56% year-on-year [1] - Net profit attributable to shareholders was 4.459 billion yuan, up 51.56% year-on-year [1] - Net profit excluding non-recurring items was 2.1 billion yuan, down 22.38% year-on-year [1] - Basic earnings per share were reported at 1.20 yuan [1]